
Opinion|Videos|November 29, 2023
Momelotinib in MF: Data from the SIMPLIFY-1 Trial
Author(s)Anthony Hunter, MD
The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
3
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
4
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
5




































